Feature | January 23, 2014

Study Finds No Significant Differences Between Commonly Used Carotid Stenting Systems in U.S.

Rates of death and stroke similarly low for three major systems

Carotid Stent Clinical Study Abbott Cordis National Cardiovascular Data Registry

Abbott Acculink Carotid Stent

January 23, 2014 — The three most common systems to place stents in blocked carotid arteries of the neck have similarly low rates of complication and death among U.S. patients, according to a study published by JACC: Cardiovascular Interventions.
“We found low rates of in-hospital death and stroke with carotid stenting regardless of the devices used on the order of 2 percent,” said lead author Jay Giri, M.D., M.P.H., assistant professor of clinical medicine at the University of Pennsylvania. “A tremendous amount of time and energy has been spent theorizing about various technical considerations of carotid stenting systems that might make one superior to another. Our study effectively argues that continued focus on these specific technical aspects is unlikely to significantly improve stroke and death rates around carotid stenting. The bottom line is that our finding should provide support for operators to use their judgment to select the stent most favorable for a particular anatomic or clinical situation.”
The study analyzed 12,135 consecutive carotid stent procedures in the National Cardiovascular Data Registry performed between January 2007 and March 2012. Penn researchers compared rates of in-hospital combined death/stroke among patients treated with Acculink/Accunet (Abbott), Xact/Emboshield (Abbott) and Precise/Angioguard (Cordis) stent/embolic protection device (EPD) combinations. The study found that in nearly 80 percent of cases examined, physicians paired stents with the corresponding EPD produced by the stent manufacturer. 
“In other types of non-carotid stenting, doctors often mix and match products from different companies,” Giri said. “With carotids, by and large, they don’t. They use companion stents and embolic protection devices from one company.”
Factors that may influence this pattern of use include that the U.S. Food and Drug Administration (FDA) approves carotid stenting systems as a unit of stent and EPD; operators may be more comfortable using an FDA-approved unit rather than “mixing and matching” stents with other EPDs; and reimbursement restrictions from Centers for Medicare & Medicaid Services (CMS).
The National Cardiovascular Data Registry supported this research by funding for statistical support.
For more information: www.upenn.edu

Related Content

St. Jude Medical, ADO II AS trial, congenital heart disease, PDA, Amplatzer Duct Occluder II AS
News | Congenital Heart| October 19, 2016
St. Jude Medical Inc. announced the launch of the ADO II AS (AMPLATZER Duct Occluder II Additional Sizes) pediatric...
Lantheus, flurpiridaz F-18, myocardial perfusion imaging, MPI, cardiac stress testing, ASNC 2016
News | Radiopharmaceuticals and Tracers| October 17, 2016
Lantheus Holdings Inc. announced in late September that sub-analysis data from the first Phase 3 study of flurpiridaz F...
Medtronic, FIRE AND ICE trial, Arctic Front, cryoballoon catheter ablation, radiofrequency RF ablation, study results, Asia Pacific Heart Rhythm Society Scientific Sessions
News | Ablation Systems| October 17, 2016
Medtronic plc last week unveiled new health economic analysis data from the FIRE AND ICE trial that favor cryoballoon...
transcarotid artery revascularization, TCAR Surveillance Project, Society for Vascular Surgery Patient Safety Organization, SVS PSO,
News | Stents Carotid| October 13, 2016
A surveillance project to evaluate the safety and effectiveness of transcarotid artery revascularization (TCAR) in...
Shockwave lithoplasty system, VIVA 16, Vascular Interventioanl Advances, VIA Physicians, late-breaking endovascular clinical trial results
News | Cath Lab| October 12, 2016
VIVA (Vascular Interventional Advances) Physicians announced a number of highly anticipated late-breaking clinical...
ZipLine Medical, Zip Surgical Skin Closure, cath lab time savings, PACE study
News | EP Lab| October 10, 2016
October 10, 2016 — ZipLine Medical Inc.
Mercator MedSystems, Bullfrog Micro-Infusion Device, DANCE trial, VIVA 2016, 13-month results
News | Peripheral Arterial Disease (PAD)| October 07, 2016
Mercator MedSystems recently announced that 13-month data from the DANCE trial was presented during a late-breaking...
Keystone Heart, TriGuard Embolic Protection Device, Neuro-TAVR study, brain lesions, American Journal of Cardiology
News | Heart Valve Technology| October 03, 2016
Keystone Heart Ltd. announced data recently published in the American Journal of Cardiology demonstrating new brain...
TCT 2016, TCT.16, main arena, late breaking trials
Feature | Cath Lab| September 28, 2016
September 28, 2016 — The Cardiovascular Research Foundation (CRF) has announced the 11 late-breaking trials and 16 fi
News | Pharmaceuticals| September 26, 2016
Nearly 2 out of 5 people with diabetes who could benefit from statin therapy to lower their risk of future heart attack...
Overlay Init